Min.Order / FOB Price:Get Latest Price
1 Kilogram |
FOB Price:USD 1.0000 -10.0000 |
Sorafenib(co-developedandco-marketedbyBayerandOnyxPharmaceuticalsasNexavar),[1]isadrugapprovedforthetreatmentofprimarykidneycancer(advancedren
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar),[1] is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
Sorafenib (a bi-aryl urea[2]) is a small molecular inhibitor of several Tyrosine protein kinases (VEGFR and PDGFR) and Raf kinases (more avidly C-Raf than B-Raf).[3][4]
(Protein kinases are overactive in many of the molecular pathways that cause cells to become cancerous. These pathways include Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 and 3 kinases and c Kit the receptor for Stem cell factor. )
Sorafenib is/was unique in targeting the View All
CAS NO:162515-68-6
CAS NO:142569-70-8
CAS NO:113020-21-6
CAS NO:3697-66-3
CAS NO:1750-42-1
CAS NO:168960-19-8
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View